Literature DB >> 12761890

Identification of a domain within MDMX-S that is responsible for its high affinity interaction with p53 and high-level expression in mammalian cells.

Ravikumar Rallapalli1, Gordon Strachan, Rocky S Tuan, David J Hall.   

Abstract

The MDMX gene product is related to the MDM2 oncoprotein, both of which interact with the p53 tumor suppressor. A novel transcript of the MDMX gene has been previously identified that has a short internal deletion of 68 base pairs, producing a shift in the reading frame after codon 114, resulting in the inclusion of 13 novel amino acids (after residue 114) followed by a stop codon at amino acid residue 127. This truncated MDMX protein, termed MDMX-S, represents only the p53 binding domain and binds and inactivates p53 better than full-length MDMX or MDM2. Here we show that when expressed in cells, MDMX-S is targeted more efficiently to the nucleus than MDMX. MDMX-S suppresses p53-mediated transcription from a p53 target promoter better than full-length MDMX. The DNA damage inducibility of these p53 responsive promoters was suppressed better by MDMX-S than by MDMX. Analysis of the MDMX-S protein indicated that the 13 novel amino acids at its carboxy terminus was responsible for high affinity binding to p53 in vitro and for high level expression of the protein in cells. Deletion of this 13 amino acid sequence resulted in a protein that was not able to bind p53 and was not able to be expressed well in cells. Taken together, these data point to an important domain within MDMX-S that enables it to function well in vivo to block p53 activity. Published 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12761890     DOI: 10.1002/jcb.10535

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  18 in total

1.  MDMX promotes proteasomal turnover of p21 at G1 and early S phases independently of, but in cooperation with, MDM2.

Authors:  Yetao Jin; Shelya X Zeng; Xiao-Xin Sun; Hunjoo Lee; Christine Blattner; Zhixiong Xiao; Hua Lu
Journal:  Mol Cell Biol       Date:  2007-12-17       Impact factor: 4.272

2.  14-3-3gamma binds to MDMX that is phosphorylated by UV-activated Chk1, resulting in p53 activation.

Authors:  Yetao Jin; Mu-Shui Dai; Steven Z Lu; Yingda Xu; Zhijun Luo; Yingming Zhao; Hua Lu
Journal:  EMBO J       Date:  2006-03-02       Impact factor: 11.598

3.  Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage.

Authors:  Daniel J Colacurcio; Alyssa Yeager; Dennis L Kolson; Kelly L Jordan-Sciutto; Cagla Akay
Journal:  Mol Cell Neurosci       Date:  2013-10-12       Impact factor: 4.314

Review 4.  MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Authors:  Jin Wu; Guanting Lu; Xinjiang Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 5.  Targeting Mdm2 and Mdmx in cancer therapy: better living through medicinal chemistry?

Authors:  Mark Wade; Geoffrey M Wahl
Journal:  Mol Cancer Res       Date:  2009-01       Impact factor: 5.852

6.  Mice engineered for an obligatory Mdm4 exon skipping express higher levels of the Mdm4-S isoform but exhibit increased p53 activity.

Authors:  B Bardot; R Bouarich-Bourimi; J Leemput; V Lejour; A Hamon; L Plancke; A G Jochemsen; I Simeonova; M Fang; F Toledo
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

Review 7.  MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and Beyond.

Authors:  Jean-Christophe Marine; Aart G Jochemsen
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

Review 8.  Functions of MDMX in the modulation of the p53-response.

Authors:  Kristiaan Lenos; Aart G Jochemsen
Journal:  J Biomed Biotechnol       Date:  2011-03-22

9.  MDM4 (MDMX) and its Transcript Variants.

Authors:  F Mancini; G Di Conza; F Moretti
Journal:  Curr Genomics       Date:  2009-03       Impact factor: 2.236

10.  Analysis of MDM2 and MDM4 single nucleotide polymorphisms, mRNA splicing and protein expression in retinoblastoma.

Authors:  Justina McEvoy; Anatoly Ulyanov; Rachel Brennan; Gang Wu; Stanley Pounds; Jinghui Zhang; Michael A Dyer
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.